New funding will help Cardiff University researchers further potential treatments for prostate cancer, through the first drug to target the BLC3 cell signalling pathway.
Prostate Cancer UK have awarded £0.5 million to prostate cancer research at the European Cancer Stem Cell Research Institute at Cardiff University, funding the investigation of the potential for a new drug for future cancer therapies.
The grant will fund investigations into targeting the BCL3 cell signalling pathway, a signal given off by cancer cells to trigger growth, which contributes to development of cancers. The researchers have developed the first ever drug that targets this pathway and aim to test the effectiveness of this potential future prostate cancer treatment.
Dr Helen Pearson, Senior Lecturer in Prostate Cancer at the School of Biosciences, said: "In aggressive prostate cancer, the BCL3 signalling pathway is often over-active, leading to the development of tumours."
